Adicet Bio (ACET)

• Market cap: $48.4M
• 1 day: -4.62%
• 5 days: 5.17%
• 1 month: -33.81%
• 3 months: -35.63%
• 6 months: -58.16%
• Year to date: -39.84%
• 1 year: -67.64%
• 5 years: -52.76%
• 10 years: -96.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Employees: 152

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

2% more funds holding

Funds holding: 63 [Q3] → 64 (+1) [Q4]

1.12% more ownership

Funds ownership: 68.81% [Q3] → 69.92% (+1.12%) [Q4]

30% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 23

32% less capital invested

Capital invested by funds: $81.6M [Q3] → $55.4M (-$26.2M) [Q4]

48% less call options, than puts

Call options by funds: $27K | Put options by funds: $52K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7 1,095% upside
• Avg. target: $7 1,095% upside
• High target: $7 1,095% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Guggenheim Yatin Suneja 29% 1-year accuracy 10 / 34 met price target

1,095% upside $7

Buy Reiterated

21 Mar 2025